日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Nivolumab with definitive chemoradiotherapy for oesophageal squamous cell carcinoma (NOBEL): a multicentre, single-arm, phase 2 feasibility trial

纳武利尤单抗联合根治性放化疗治疗食管鳞状细胞癌（NOBEL）：一项多中心、单臂、II期可行性试验

期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2025.103689
Nomura, Motoo; Sakanaka, Katsuyuki; Shimizu, Juko; Ohashi, Shinya; Katada, Chikatoshi; Watanabe, Akinori; Amanuma, Yusuke; Minashi, Keiko; Kato, Ken; Kojima, Takashi; Nagashima, Kengo; Kim, Ihhwa; Tada, Harue; Nakakura, Akiyoshi; Muto, Manabu
细胞生物学
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Treatment resistance factors associated with Talaporfin sodium photodynamic therapy for local control after chemoradiotherapy for esophageal cancer

食管癌放化疗后局部控制中，他拉泊芬钠光动力疗法相关的治疗耐药因素

期刊:Esophagus
影响因子:3.8
doi:10.1007/s10388-025-01177-w
Tamaoki, Masashi; Yokoyama, Akira; Katada, Chikatoshi; Hirohashi, Kenshiro; Mitani, Yosuke; Amanuma, Yusuke; Horimatsu, Takahiro; Higuchi, Hirokazu; Yamahigashi, Natsuko; Nomura, Motoo; Inoo, Hiroyuki; Sakanaka, Katsuyuki; Nikaido, Mitsuhiro; Shimizu, Takahiro; Kishimoto, Yo; Tsunoda, Shigeru; Obama, Kazutaka; Ohashi, Shinya; Muto, Manabu
食管癌
肿瘤
肿瘤免疫
治疗耐药
发表日期：2026
文献求助 收藏

IL33-ST2 axis is a predictive biomarker for anti-PD1 therapeutic efficacy in advanced gastric cancer

IL33-ST2轴是晚期胃癌抗PD-1治疗疗效的预测性生物标志物

期刊:Journal of Translational Medicine
影响因子:7.5
doi:10.1186/s12967-025-07145-3
Kudo-Saito, Chie; Imazeki, Hiroshi; Nagashima, Kengo; Shoji, Hirokazu; Tsugaru, Kai; Takahashi, Naoki; Kawakami, Takeshi; Amanuma, Yusuke; Wakatsuki, Takeru; Okano, Naohiro; Narita, Yukiya; Yamamoto, Yoshiyuki; Kizawa, Rika; Muro, Kei; Ichikawa, Hitoshi; Boku, Narikazu
胃癌
肿瘤
肿瘤免疫
IL3
PD-1
发表日期：2025
文献求助 收藏

The FSTL1-DIP2A axis is a significant biomarker for predicting anti-PD1 therapeutic efficacy in advanced gastric cancer.

FSTL1-DIP2A 轴是预测晚期胃癌抗 PD-1 治疗效果的重要生物标志物。

期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-025-04239-1
Kudo-Saito Chie, Imazeki Hiroshi, Nagashima Kengo, Shoji Hirokazu, Tsugaru Kai, Takahashi Naoki, Kawakami Takeshi, Amanuma Yusuke, Wakatsuki Takeru, Nagashima Fumio, Narita Yukiya, Yamamoto Yoshiyuki, Kizawa Rika, Muro Kei, Boku Narikazu
胃癌
肿瘤
肿瘤免疫
PD-1
发表日期：2025
文献求助 收藏

Impact of antimicrobial exposure at delivery and siblings on early Bifidobacterium succession and allergy development up to 24 months of age

分娩时及同胞接触抗菌药物对24个月龄前双歧杆菌早期更替和过敏发展的影响

期刊:BMC Microbiology
影响因子:4.2
doi:10.1186/s12866-025-04056-7
Imoto, Naruaki; Kano, Chie; Morita, Hiroto; Hirota, Tatsuhiko; Amanuma, Fumitaka; Maruyama, Hidekazu; Nojiri, Shuko; Watanabe, Shin
发表日期：2025
文献求助 收藏

Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)

一项 II 期试验评估了 nab-紫杉醇联合雷莫芦单抗和纳武利尤单抗治疗一线治疗（包括氟尿嘧啶、铂类和抗 PD-1/PD-L1 抗体）后进展的不可切除的晚期或复发性胃癌的疗效（PADDLE）。

期刊:BMC Cancer
影响因子:3.4
doi:10.1186/s12885-025-13591-5
Hirano, Hidekazu; Takahashi, Naoki; Amanuma, Yusuke; Suzuki, Nobumi; Takahari, Daisuke; Kawakami, Takeshi; Kudo-Saito, Chie; Nagashima, Kengo; Boku, Narikazu; Kato, Ken; Shoji, Hirokazu
胃癌
肿瘤
肿瘤免疫
PD-L1
PD-1
发表日期：2025
文献求助 收藏

Peripheral SNCA(+) cells as a poor prognostic factor for nivolumab therapy in advanced gastric cancer

外周SNCA(+)细胞是晚期胃癌患者接受纳武利尤单抗治疗预后不良的因素

期刊:Discover Oncology
影响因子:2.9
doi:10.1007/s12672-025-03817-0
Kudo-Saito, Chie; Imazeki, Hiroshi; Nagashima, Kengo; Shoji, Hirokazu; Tsugaru, Kai; Takahashi, Naoki; Kawakami, Takeshi; Amanuma, Yusuke; Wakatsuki, Takeru; Okano, Naohiro; Narita, Yukiya; Yamamoto, Yoshiyuki; Kizawa, Rika; Muro, Kei; Boku, Narikazu
胃癌
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Novel T1 Analysis Method to Address Reduced Measurement Accuracy Due to Irregular Heart Rate Variability in Myocardial T1 Mapping Using Polarity-corrected Inversion Time Preparation

一种新型T1分析方法，利用极性校正反转时间准备技术，解决因心率变异性不规则导致的心肌T1映射测量精度降低问题。

期刊:
影响因子:
doi:10.2463/mrms.mp.2023-0029
Endo, Yuta; Takahashi, Sanae; Shibo, Haruna; Amanuma, Makoto; Kobayashi, Kuninori; Kuhara, Shigehide
发表日期：2025
文献求助 收藏

Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study)

髓系细胞亚群会阻碍抗PD-1疗法在晚期胃癌患者中的疗效（WJOG10417GTR研究）

期刊:Journal for ImmunoTherapy of Cancer
影响因子:10.6
doi:10.1136/jitc-2024-010174
Shoji, Hirokazu; Kudo-Saito, Chie; Nagashima, Kengo; Imazeki, Hiroshi; Tsugaru, Kai; Takahashi, Naoki; Kawakami, Takeshi; Amanuma, Yusuke; Wakatsuki, Takeru; Okano, Naohiro; Narita, Yukiya; Yamamoto, Yoshiyuki; Kizawa, Rika; Muro, Kei; Aoki, Kazunori; Boku, Narikazu
胃癌
肿瘤
肿瘤免疫
细胞生物学
PD-1
发表日期：2024
文献求助 收藏

Pattern of disease progression during third-line or later chemotherapy with nivolumab associated with poor prognosis in advanced gastric cancer: a multicenter retrospective study in Japan

日本一项多中心回顾性研究显示，在接受纳武利尤单抗治疗的三线或后续化疗期间，晚期胃癌患者的疾病进展模式与预后不良相关。

期刊:Gastric Cancer
影响因子:5.1
doi:10.1007/s10120-022-01349-y
Aoki, Masahiko; Kadowaki, Shigenori; Takahashi, Naoki; Suzuki, Takeshi; Oshima, Kotoe; Ando, Takayuki; Yamamoto, Yoshiyuki; Kawakami, Kentaro; Kito, Yosuke; Matsumoto, Toshihiko; Shimozaki, Keitaro; Miyazaki, Yasuhiro; Yamaguchi, Toshifumi; Nagase, Michitaka; Tamura, Takao; Amanuma, Yusuke; Esaki, Taito; Miura, Yuji; Akiyoshi, Kohei; Baba, Eishi; Makiyama, Akitaka; Negoro, Yuji; Nakashima, Koji; Sugimoto, Naotoshi; Nagashima, Kengo; Shoji, Hirokazu; Boku, Narikazu
胃癌
肿瘤
肿瘤免疫
发表日期：2023
文献求助 收藏